Agilent Technologies Triple Quadrupole ICP-MS Selected for R&D 100 Award
News Jul 15, 2013
Agilent Technologies Inc. announce that the 8800 Triple Quadrupole ICP-MS has been named an R&D 100 Award winner.
“The Agilent 8800 Triple Quadrupole ICP-MS is a groundbreaking innovation that redefines the possibilities of ultra-trace elemental analysis,” said Philip Binns, Agilent vice president for spectroscopy products. “The 8800 ICP-QQQ has enjoyed strong adoption in its first year and has defined a new segment in elemental analysis. We are honored that our spectroscopy division has won this award for two consecutive years.”
Unlike existing instruments, the Agilent 8800 is the only ICP-MS system with a tandem mass spectrometer, or MS/MS, configuration. Using a high-performance quadrupole before and after the collision/reaction cell, the 8800 precisely controls the ions in the instrument, allowing the user to resolve the most difficult interferences and obtain the highest sensitivity results of any ICP-MS.
The Agilent 8800 enables scientists and chemists to solve challenging analytical problems that have proven difficult for conventional ICP-MS systems in traditional markets such as semiconductors, environmental and food. Additionally, the 8800 offers new research capabilities providing scientists new application possibilities in fields such as life sciences.
The R&D 100 Awards have long been a benchmark of excellence for industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing and biotechnology. Winners are selected by an independent judging panel and the editors of R&D Magazine.
In 2012, the Agilent 4100 Microwave Plasma-Atomic Emission Spectrometer (MP-AES) won an R&D 100 Award.
A skin swab test for Parkinson's has become a real possibility, after mass spectrometry was used to detect altered levels of specific compounds on the skin of people with the condition. The research is a result of the incredible ability of one woman to detect a unique odor on the skin of people with Parkinson's disease. These findings open the door to a non-invasive screening test.READ MORE